Back to top

Analyst Blog

Endocyte, Inc. (ECYT - Snapshot Report) reported second quarter 2013 net loss per share of 23 cents, wider than the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 15 cents.

Second quarter 2013 revenues were $16.5 million compared with $7.8 million in the second quarter 2012. Revenues comprised solely of collaboration revenues. Revenues surpassed the Zacks Consensus Estimate of $15 million.

In the reported quarter, research and development expenses were $18.6 million, up 111.4%. Costs related to the PROCEED and TARGET trials were primarily responsible for the increase. In the reported quarter, general and administrative (G&A) expenses jumped 93.8% to $6.2 million. The increase was attributable to establishing commercial capability. An increase in compensation expenses was also responsible for pushing G&A costs up.

In 2012, Endocyte had submitted a marketing authorization application (MAA) seeking approval for vintafolide for platinum-resistant ovarian cancer. The company is also seeking EU approval for a folate-targeted molecular imaging agent, etarfolatide. Both candidates were granted orphan drug status in the EU in 2012. The company expects a decision from the European Commission on both candidates in the fourth quarter of 2013.

Endocyte completed enrollment in the phase IIb TARGET study of vintafolide in non-small cell lung cancer (NSCLC) patients. Top-line data from the study is expected in the first quarter of 2014

Endocyte and its partner,  Merck & Co. Inc. (MRK - Analyst Report), will initiate a phase II randomized trial on vintafolide in folate receptor-positive triple negative breast cancer in the fourth quarter of 2013.

In the first half of 2014, Endocyte expects to complete enrollment in the phase III PROCEED study.

For its folate-targeted tubulysin therapeutic, Endocyte will file an investigational new drug application and initiate a study in the third quarter of 2013.

Endocyte maintained its cash, cash equivalents and investments guidance in the range of $145 - $160 million as provided on Dec 31, 2013.

Endocyte carries a Zacks Rank #3 (Hold). In the reported quarter, Endocyte completed the enrollment in the TARGET study ahead of schedule. The company is also working towards a strong foothold in the European market.

Currently, companies like Questcor Pharmaceuticals Inc. and NPS Pharmaceuticals, Inc. (NPSP - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SIGNET JEWE… SIG 116.37 +7.72%
CHYRONHEGO… CHYR 2.72 +5.84%
US SILICA H… SLCA 70.72 +4.00%
MALLINCKROD… MNK 80.11 +2.32%
RF MICRO DE… RFMD 11.76 +2.31%